Compare HTHT & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTHT | DAWN |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 2.2B |
| IPO Year | 2010 | 2021 |
| Metric | HTHT | DAWN |
|---|---|---|
| Price | $43.21 | $21.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $56.60 | $24.43 |
| AVG Volume (30 Days) | 1.7M | ★ 2.7M |
| Earning Date | 05-19-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $7.18 | $55.03 |
| Revenue Next Year | $6.71 | $28.12 |
| P/E Ratio | $30.34 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $30.42 | $5.64 |
| 52 Week High | $56.53 | $21.53 |
| Indicator | HTHT | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 30.45 | 80.29 |
| Support Level | $41.73 | $10.30 |
| Resistance Level | $50.62 | N/A |
| Average True Range (ATR) | 1.49 | 0.03 |
| MACD | -0.28 | -0.28 |
| Stochastic Oscillator | 1.91 | 90.91 |
H World Group Ltd a foremost, fast-growing multi-brand hotel group with international operations. The principal business activities of the Company are to develop and operate leased and owned, manachised and franchised hotels mainly in the PRC or PRC Mainland. The Group has two operating segments which are legacy Huazhu and legacy DH according to the way management intends to evaluate results and allocate resources within the Group. The majority of revenue comes from legacy Huazhu. The company has presence in Greater China and also Outside Greater China.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.